<DOC>
	<DOCNO>NCT02028806</DOCNO>
	<brief_summary>This phase Ⅱ study design evaluate efficacy safety mFOLFIRINOX first-line treatment metastatic pancreatic cancer China .</brief_summary>
	<brief_title>mFOLFIRINOX First-Line Chemotherapy Treating Chinese Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Although FOLFIRINOX regimen recently present effective metastatic pancreatic cancer select patient good physical condition , still insufficient evidence regimen treat patient metastatic pancreatic cancer China . Since many tumor , different race may show different response regimen , design open , multicenter phase Ⅱ study evaluate efficacy safety mFOLFIRINOX first-line treatment metastatic pancreatic cancer China .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Patients provide sign Informed Consent Form ECOG performance status 01 BMI ≥ 18.5 Age : 1865 year old Histologically confirm diagnosis metastatic pancreatic cancer No prior palliative chemotherapy Measurable disease least 1 diameter CT scan MRI per RECIST 1.1 criterion Life expectancy ≥ 3 month Patient adequate bone marrow organ function Absolute Neutrophil Count ( ANC ) ≥ 2.0 x 109/L Platelets ≥ 90 x 109/L Hemoglobin ≥ 90 g/L Patient adequate liver function AST ALT 2.5 time ULN ( 5.0 time ULN liver metastasis ) Serum bilirubin ≤ 1.2 x ULN Creatinine ≤ 1.25 time ULN Good compliance Pregnant lactate woman Brain metastasis bone metastasis . Patients severe gastrointestinal hemorrhage need frequent blood transfusion . Refuse take appropriate contraceptive measure ( include male patient ) . Allergic Oxaliplatin , Irinotecan , Leucovorin 5Fluorouracil . Severe systemic disease control unstable uncompensated respiratory , cardiac , liver , renal disease . Patient concurrent malignancy malignancy within 5 year study enrollment , ( exception nonmelanoma skin cancer cervical carcinoma situ ) . Psychiatric illness would prevent patient give informed consent . Patient concurrently use antineoplastic agent Patient use investigational antineoplastic agent within 4 week prior entry . Known HIVpositivity . No history chronic diarrhea , nausea vomit . No ≥ grade 2 sensory peripheral neuropathy . A history transmural myocardial infarction ( within 6 month prior entry ) , congestive heart failure , unstable angina . Infectious disease inflammation body temperature ≥ 38 ℃ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>